A randomized crossover trial suggests whole grains may be a helpful nutritional tool for lowering cardiovascular-related mortality tied to a key risk factor — diastolic blood pressure — in overweight younger adults.
A global registry study has found high rates of mortality from infective endocarditis following TAVR. A study co-author and an ID specialist discuss the study’s surprises and how to curb post-TAVR infection risk.
A cohort study has tied the gut microbial metabolite TMAO to elevated five-year mortality in patients with peripheral artery disease (PAD). Here’s how treatment targeting in PAD may be shaped in response.
One in three patients with CIED infections referred to Cleveland Clinic for extraction in recent years had methicillin-resistant staphylococci. Here’s why that’s worrisome and what can be done.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A new study in JAMA shows it’s possible to ease cardiac telemetry alarm fatigue while actually reducing cardiopulmonary arrest events. The secret lies in a dedicated off-site central monitoring unit.
A large observational study shows that elevated right ventricular systolic pressure worsens survival in patients with mitral regurgitation — and suggests mitral valve repair might be indicated sooner than we thought.
Retrievable inferior vena cava filters continue to be left in many patients long after the risk of embolism has passed. A vascular medicine specialist shares advice on how to minimize such oversights.
A study presented at EuroPCR raised eyebrows when researchers suggested half of TAVR valves may degenerate within 10 years. This Q&A with Cleveland Clinic valve experts puts the findings in context.
A new analysis of the SRTR registry does more than show which underlying conditions confer high mortality on the heart transplant wait list. It also reveals the need to tweak the allocation system.
Cleveland Clinic is now enrolling patients at three U.S. sites in a phase 3 global trial of the biologic aducanumab for treatment of mild cognitive impairment or early Alzheimer disease.